3 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow Opioid Withdrawal: new trials by email Literature Review of Opioid Withdrawal trials Research Report on Opioid Withdrawal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Cannabidiol for Opioid Withdrawal Epidiolex, Placebo - Opioid Withdrawal, Opioid Craving | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 3 | 2020-11-01 | 2023-08-29 |
| Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Dexmedetomidine, Placebo - Opioid Withdrawal | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 225 | 2020-06-09 | 2026-08-11 |
| Oxytocin Treatment of Opioid Dependence Intranasal Oxytocin Spray, Placebo - Opioid Dependence, Opioid Withdrawal | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 12 | 2016-02-01 | 2019-08-07 |
Opioid-Related Disorders (3) · Morphine Dependence (1) · Psychomotor Agitation (1)
Chemically-Induced Disorders (3) · Mental Disorders (3) · Narcotic-Related Disorders (3) · Substance-Related Disorders (3) · Aberrant Motor Behavior in Dementia (1) · Behavior (1) · Behavioral Symptoms (1) · Dyskinesias (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Psychomotor Disorders (1) · Signs and Symptoms (1)
Cannabidiol (1) · Dexmedetomidine (1)
BioXcel Therapeutics Inc (1) · Johns Hopkins University (1) · University of North Carolina, Chapel Hill (1)
United States (3)
BioXcel MM, MD (1) · Cecilia L Bergeria, PhD (1) · Cort A Pedersen, MD (1) · James C Garbutt, MD (1)